Resources from the same session
393MO - Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer
Presenter: Rolf A. Stahel
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
322MO - Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
Presenter: Byoung Chul Cho
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
305MO - SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
Presenter: Yongfeng Yu
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: Alfredo Addeo
Session: Mini Oral session: Thoracic cancers
Resources:
Slides
Webcast
LBA11 - Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced <italic>ALK</italic>+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study
Presenter: Thanyanan Baisamut (Reungwetwattana)
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
320MO - Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial
Presenter: Wen Feng Fang
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
321MO - Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
Presenter: James Chih-Hsin Yang
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA11, 320MO and 321MO
Presenter: Hidehito Horinouchi
Session: Mini Oral session: Thoracic cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Alfredo Addeo
Session: Mini Oral session: Thoracic cancers
Resources:
Slides
Webcast
LBA5 - Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
Presenter: Thomas John
Session: Mini Oral session: Thoracic cancers
Resources:
Abstract
Slides
Webcast